Sven-Erik Dahlén svensk läkare
Dahlén, Sven-Erik, 1952-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Dahlén, Sven-Erik
VIAF ID: 58138631 (Personal)
Permalink: http://viaf.org/viaf/58138631
Preferred Forms
-
100 1 _ ‡a Dahlén, Sven-Erik
-
100 1 0
‡a
Dahlén, Sven-Erik
-
100 1 _ ‡a Dahlén, Sven-Erik
-
100 1 _ ‡a Dahlén, Sven-Erik (sparse)
-
100 1 _
‡a
Dahlén, Sven-Erik,
‡d
1952-....
-
100 1 _
‡a
Dahlén, Sven-Erik
-
100 1 _ ‡a Dahlén, Sven-Erik
-
100 1 _
‡a
Dahlén, Sven-Erik
-
100 1 _ ‡a Dahlén, Sven-Erik ‡d (1952- )
-
100 1 _ ‡a Dahlén, Sven-Erik ‡d (1952- ).
-
100 1 _
‡a
Dahlén, Sven-Erik
‡d
1952-
-
100 1 _
‡a
Dahlén, Sven-Erik,
‡d
1952-
-
100 1 _ ‡a Dahlén, Sven-Erik, ‡d 1952-
-
100 0 _
‡a
Sven-Erik Dahlén
‡c
svensk läkare
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Five-lipoxygenase products in asthma |
|
| Health-related quality of life, assessed with a disease-specific questionnaire, in Swedish adults suffering from well-diagnosed food allergy to staple foods |
|
| High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma |
|
| Higher risk of wheeze in female than male smokers. Results from the Swedish GA 2 LEN study |
|
| Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69-CD56dim cells |
|
| Human tissue models for a human disease: what are the barriers? |
|
| Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma |
|
| Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial |
|
| Increased prevalence of symptoms of rhinitis but not of asthma between 1990 and 2008 in Swedish adults: comparisons of the ECRHS and GA²LEN surveys |
|
| Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease |
|
| The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma |
|
| Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction |
|
| Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor |
|
| Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung |
|
| International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma |
|
| [International guidelines for allergic rhinitis have been updated] |
|
| International research collaboration: The way forward |
|
| International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors |
|
| Intranasal administration of poly |
|
| Jaki lek przeciwzapalny powinniśmy stosować w leczeniu astmy |
|
| Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome |
|
| Leukotriene E4 induces airflow obstruction and mast cell activation via the CysLT1 receptor. |
|
| Leukotrienes as mediators of asthma and inflammation : basic and applied research |
|
| Leukotrienes : new concepts and targets for therapy : proceedings of a conference held on June 12-13, 1997 in London, UK |
|
| Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD. |
|
| Lipid mediator profiling in pulmonary disease |
|
| Lipid Mediator Quantification in Isolated Human and Guinea Pig Airways: An Expanded Approach for Respiratory Research |
|
| Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids |
|
| Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers |
|
| Lipoxin A4 reduces house dust mite and TNFα-induced hyperreactivity in the mouse trachea |
|
| The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo |
|
| Mannitol triggers mast cell-dependent contractions of human small bronchi and prostacyclin bronchoprotection |
|
| Mast cell engraftment of the peripheral lung enhances airway hyperresponsiveness in a mouse asthma model |
|
| Mast cell mediators cause the early allergic bronchoconstriction in guinea pigs in vivo: a model of relevance to asthma |
|
| Modulation of antigen-induced responses by serotonin and prostaglandin E2 via EP1 and EP4 receptors in the peripheral rat lung |
|
| No further increase of incidence of asthma: incidence, remission and relapse of adult asthma in Sweden |
|
| The number needed to treat provides additional insight on the performance of detection points of asthma exacerbations in self-management plans: authors' response on behalf of the BIOAIR consortium |
|
| The occurrence of refractoriness and mast cell mediator release following mannitol-induced bronchoconstriction. |
|
| Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle |
|
| Pharmacological modulation of the leukotriene pathway in allergic airway disease |
|
| Phenotypic predictors of response to oral glucocorticosteroids in severe asthma |
|
| Predicting asthma morbidity in children using proposed markers of Th2-type inflammation |
|
| Professor Andrzej Szczeklik (1938-2012) : a European intellectual defining aspirin-asthma and much more |
|
| Progress in allergy and clinical immunology. |
|
| Prostaglandin D₂ induces contractions through activation of TP receptors in peripheral lung tissue from the guinea pig. |
|
| Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. |
|
| Prostaglandin E2 suppresses human group 2 innate lymphoid cell function. |
|
| Pulmonary effects of leukotrienes |
|
| Quality of life in relation to the traffic pollution indicators NO2 and NOx: results from the Swedish GA(2)LEN survey |
|
| Quantification of lipid mediator metabolites in human urine from asthma patients by electrospray ionization mass spectrometry: controlling matrix effects. |
|
| Quantitative metabolic profiling of urinary eicosanoids for clinical phenotyping |
|
| Refractoriness to exercise challenge: a review of the mechanisms old and new. |
|
| RNA-containing exosomes in induced sputum of asthmatic patients |
|
| Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma |
|
| Selective COX-2 Inhibition Exerts No Negative Effects on Peripheral Blood Lymphocytes in Allergic Asthmatics |
|
| Severe asthma in adults: what are the important questions? |
|
| Slow-reacting substance of anaphylaxis to leukotrienes |
|
| Socio-economic impact of objectively-diagnosed allergy to staple foods in children and adolescents. |
|
| Soluble epoxide hydrolase derived lipid mediators are elevated in bronchoalveolar lavage fluid from patients with sarcoidosis: a cross-sectional study |
|
| Solution-engineered palladium nanoparticles: model for health effect studies of automotive particulate pollution |
|
| Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction |
|
| [Spirometry screening can identify new cases of asthma and COPD. Public lung function tests at the Stockholm's Central Station] |
|
| Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma |
|
| Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12-18 months |
|
| SRS-A to leukotrienes : the dawning of a new treatment |
|
| [TNF-blockade--new strategy in difficult-to-treat asthma] |
|
| TNFα-blockade stabilizes local airway hyperresponsiveness during TLR-induced exacerbations in murine model of asthma. |
|
| Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation |
|
| Toward clinically applicable biomarkers for asthma: An EAACI position paper |
|
| Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics. |
|
| Treatable Traits in the European U-BIOPRED Adult Asthma Cohorts |
|
| Treatment of asthma with antileukotrienes: first line or last resort therapy? |
|
| TSLP in asthma--a new kid on the block? |
|
| Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics |
|
| U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics |
|
| Update of prevalence of self-reported allergic rhinitis and chronic nasal symptoms among adults in Sweden |
|
| Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7 |
|
| Urinary excretion of lipid mediators in response to repeated eucapnic voluntary hyperpnea in asthmatic subjects |
|
| Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type-2 Inflammation |
|
| Volatile Organic Compounds Breathprinting of U-BIOPRED Severe Asthma smokers/ex-smokers cohort |
|
| Which anti-inflammatory drug should we use in asthma? |
|
| Will recording of lung function fluctuation open the door to internet-guided treatment of asthma? |
|
| YKL-40 is a proposed biomarker of inflammation and remodelling elevated in children with bronchopulmonary dysplasia compared to asthma |
|
